Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989941 | 1.00 | MAPK1 (0.43) | MAPK1GPBAR1LIPEPIK3CAPTGDR2 | |
| SCHEMBL30989814 | 0.90 | MAPK1 (0.36) | MAPK1GPBAR1LIPETRPM8PIK3C3 | |
| SCHEMBL30989905 | 0.89 | KDM4C (0.40) | GPBAR1PTGDR2PIK3C3KDM4C | |
| SCHEMBL30990026 | 0.88 | MAPK1 (0.41) | MAPK1GPBAR1PTGDR2PIK3C3KDM4C | |
| SCHEMBL30989831 | 0.88 | MAPK1 (0.41) | MAPK1GPBAR1PTGDR2PIK3C3KDM4C | |
| SCHEMBL30989913 | 0.85 | GPBAR1 (0.36) | GPBAR1PTGDR2TRPM8PIK3C3KDM4C | |
| SCHEMBL30989852 | 0.85 | GPBAR1 (0.36) | GPBAR1PTGDR2TRPM8PIK3C3KDM4C | |
| SCHEMBL30989894 | 0.83 | SPR (0.47) | GPBAR1LIPETRPM8 | |
| SCHEMBL30989842 | 0.83 | SPR (0.47) | GPBAR1LIPETRPM8 | |
| SCHEMBL30989956 | 0.80 | MAPK1 (0.54) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |